Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Jason S. Fritz, MD, FCCP

Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)
Co-Director, Penn Presbyterian Dyspnea Program
PennChart Governance Divisional Liaison, Penn Medicine
Director, Penn Medicine University City, Pulmonary Function Lab
Department: Medicine

Contact information
Harron Lung Center
Pulmonary Vascular Disease Program
Penn Medicine University City
3737 Market St., 10th Floor
Philadelphia, PA 19104
Office: 215-662-8766
Fax: 215-243-3625
Education:
B.S. (Biology with honors, cum laude)
Bucknell University, 1999.
M.D. (Medicine)
Temple University School of Medicine, 2003.
Post-Graduate Training
Internal Medicine Residency, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2003-2006.
Pulmonary and Critical Care Fellowship, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Case Western Reserve University, Cleveland, OH, 2007-2010.
Certifications
American Board of Internal Medicine, Diplomate in Internal Medicine, 2006.
American Board of Internal Medicine, Diplomate in Pulmonary Disease, 2009.
American Board of Internal Medicine, Diplomate in Critical Care Medicine, 2010.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

1. Pulmonary hypertension: Diagnosis & management
2. Consultative pulmonology & second opinions
3. Cardiopulmonary exercise testing and the evaluation of unexplained dyspnea (shortness of breath)

Description of Other Expertise

Dr. Fritz co-directs the multidisciplinary Dyspnea Program at Penn Presbyterian Medical Center.

The Pulmonary Hypertension/Pulmonary Vascular Disease Program at the University of Pennsylvania is accredited as a Center of Comprehensive Care by the Pulmonary Hypertension Association (PHA).

Description of Research Expertise

Pulmonary vascular disease: Therapeutics, outcomes

Selected Publications

Pan HM, McClelland RL, Moutchia J, Appleby DH, Fritz JS, Holmes JH, Minhas J, Palevsky HI, Urbanowicz RJ, Kawut SM, Al-Naamani N: Heterogeneity of treatment effects by risk in pulmonary arterial hypertension. Eur Respir J 62(1): 2300190, 2023.

McCarthy BE, McClelland RL, Appleby DH, Moutchia JS, Minhas JK, Min J, Mazurek JA, Smith KA, Fritz JS, Pugliese SC, Urbanowicz RJ, Holmes JH, Palevsky HI, Kawut SM, Al-Naamani N: BMI and treatment response in patients with pulmonary arterial hypertension: a meta-analysis. Chest 162(2): 436-447, Aug 2022.

Matura LA, Fargo JD, Boyle K, Fritz JS, Smith KA, Mazurek JA, Pinder D, Archer-Chicko CL, Palevsky HI, Pack AI, Sommers MS, Kawut SM: Symptom phenotypes in pulmonary arterial hypertension: the PAH "symptome" Pulm Circ 12: e12135, July 2022.

Min J, Appleby DH, McClelland RL, Minhas J, Holmes JH, Urbanowicz RJ, Pugliese SC, Mazurek JA, Smith KA, Fritz JS, Palevsky HI, Suh JM, Al-Naamani N, Kawut SM : Secular and regional trends among pulmonary arterial hypertension clinical trial participants. Ann Am Thorac Soc 19(6): 952-961, Jun 2022.

Goodman R, Chirinos JA, Ky B, Mazurek JA, Smith KA, Palevsky HI, Fritz JS, Pugliese SC, Kawut SM, Al-Naamani N: Systemic arterial properties in pulmonary hypertension. Pulm Circ 11(4): 1-3, Dec 2021.

Herzig M, Khandhar S, Palevsky H, Fritz J, Mehta M, Matthai W: Intermediate-term outcomes for patients with submassive pulmonary embolism treated with catheter-directed thrombolysis. J Invasive Cardiol 33(12): E949-E953, Nov 2021.

Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V: Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study. J Heart Lung Transplant 38(1): 43-50, Jan 2019.

Boyle K, Fargo JD, Fritz JS, Smith KA, Mazurek JA, Pinder D, Archer-Chicko CL, Palevsky HI, Pack AI, Sommers MS, Kawut SM, Matura LA: Reliability and construct validity of the patient-reported outcomes measurement information system (PROMIS) instruments in women with pulmonary arterial hypertension. Am J Respir Crit Care Med. Poster presentation, 197: A2640, May 2018.

Narasimhan V, Palevsky HI, Smith KA, Fritz JS, Mazurek JA, Archer-Chicko CL, Burwell C, Pugliese S, Kawut SM, Al-Naamani N: Obesity in pulmonary arterial hypertension. Am J Respir Crit Care Med 197: A5709, May 2018 Notes: Poster presentation.

Baird GL, Archer-Chicko C, Barr RG, Bluemke DA, Foderaro AE, Fritz JS, Hill NS, Kawut SM, Klinger JR, Lima JAC, Mullin CJ, Ouyang P, Palevsky HI, Palmisicano AJ, Pinder D, Preston IR, Roberts KE, Smith KA, Walsh T, Whittenhall M, Ventetuolo CE: Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. Eur Respir J 51(6): 1800467, Jan 2018.

back to top
Last updated: 10/30/2023
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with a supported browser.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration